Cerus Co.

Cerus Corporation closed a new financing package with MidCap Financial providing up to $110 million, combining a five-year term loan and an asset-backed revolving loan. The refinancing included an initial $35 million draw, retirement of a $65 million term loan, access to an additional $30 million in tranches and a separate five-year revolver of up to $45 million. Management says the deal lowers annual cash interest expense by up to $3.5 million, extends maturities and features deferred amortization for 48 months followed by a 12-month repayment period. » Más en finance.yahoo.com

Cerus reported Q1 2026 EPS of $-0.01 (expectation $-0.05) and revenue of $59.9m versus expected $56.17m, driven by a 24% increase in product sales. Adjusted EBITDA was $4.0m, marking the eighth consecutive positive quarter, while gross margin fell to 52% due to inflation and currency effects. Management reaffirms disciplined cost management and expects revenue of $227m for 2026 and $256.1m for 2027 as the INTERCEPT platform continues to internationalize. The stock rose 5.73% in after-hours trading and pulled back slightly in premarket trading. » Más en de.investing.com

Cerus aims to establish the INTERCEPT blood system as a global standard in transfusion medicine and is targeting a U.S. platelet market share of over 70% in the near term. The company expects 2026 revenue of $224–228 million, roughly 60% of which will come from the U.S. A new agreement with the Blood Centers of America is intended to increase market penetration cost‑effectively; international expansions in Germany, China, Japan and Brazil are being advanced. Key milestones are expected for the INTERCEPT red blood cell program, and REDS phase‑3 data are scheduled for release in the fourth quarter. » Más en de.investing.com